NCT01103414 - Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients | Biotech Hunter

Enrollment

356

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions

Type 2 Diabetes

Interventions

DRUG

Mitoglitazone

50 mg capsules, once daily for 84 days

DRUG

Mitoglitazone

Mitoglitazone 100 mg capsules, once daily for 84 days

DRUG

Mitoglitazone

Mitoglitazone 150 mg capsules, once daily for 84 days

DRUG

Pioglitazone

Pioglitazone 45 mg, once daily for 84 days

DRUG

Placebo

Placebo, once daily for 84 days

Trial Locations (24)

Unknown

Huntsville

Muscle Shoals

Chino

Los Angeles

Spring Valley

Walnut Creek

Miami

New Port Richley

Palm Harbor

Pembroke Pines

Marietta

Chicago

Indianapolis

Grand Rapids

Cincinnati

Kettering

Tiffin

Oklahoma City

Eugene

Portland

Greer

Corpus Christi

Houston

San Antonio